Bosutinib (SKI-606)

For research use only.

Licensed by Pfizer Catalog No.S1014

69 publications

Bosutinib (SKI-606) Chemical Structure

Molecular Weight(MW): 530.45

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 437 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bosutinib (SKI-606) has been cited by 69 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy.
Targets
Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
1 nM 1.2 nM
In vitro

Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NB7 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1yzRWlEPTB;MD6wPFI{OSBizszN NE\VPY1USU6JRWK=
SW756 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfYbJUyUUN3ME2wMlE1ODJ2IDFOwG0> NH7FXoJUSU6JRWK=
CTV-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK3OmxKSzVyPUCuNVY{QThiIN88US=> M3Lz[HNCVkeHUh?=
HSC-4 M4G5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\1SGlEPTB;MD6xO|E2QCBizszN NVr3fZFvW0GQR1XS
LAMA-84 NIHX[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLtS|FjUUN3ME2wMlI5PjZ2IDFOwG0> M3LiWnNCVkeHUh?=
KU812 M2joT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\lTWM2OD1yLkO0NFY5KCEQvF2= MoLiV2FPT0WU
HCC1806 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX0bGFKSzVyPUCuN|UzOTZiIN88US=> M{e4S3NCVkeHUh?=
DOK Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnNU4NKSzVyPUCuN|c4QDZiIN88US=> MUTTRW5ITVJ?
NCI-H209 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF70dHNKSzVyPUCuOFA5ODhiIN88US=> NHLEOJVUSU6JRWK=
EoL-1-cell NW\WeINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVey[FVXUUN3ME2wMlQyPTd4IDFOwG0> NVHNPYVEW0GQR1XS
H9 NEHnbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\s[VR7UUN3ME2wMlQ{PDZ2IDFOwG0> NV3mOVI6W0GQR1XS
EM-2 NVjMXYJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nXU2lEPTB;MD60N|g6KCEQvF2= MV\TRW5ITVJ?
NCI-H292 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1SFZRUUN3ME2wMlQ1OTB6IDFOwG0> NIC2ZodUSU6JRWK=
697 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwNEW2N|MhKM7:TR?= NETaeFFUSU6JRWK=
BHT-101 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNE[1PUAh|ryP Mm\sV2FPT0WU
BE-13 NED5XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHyTWM2OD1yLkS4OVczKCEQvF2= MV;TRW5ITVJ?
RS4-11 NI\PdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD1yLkS4OVg1KCEQvF2= MlX4V2FPT0WU
IGROV-1 MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LqWWlEPTB;MD60PFc6PyBizszN NVfHbXhJW0GQR1XS
KE-37 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXETpJKSzVyPUCuOFk2ODliIN88US=> NGHkWpNUSU6JRWK=
BV-173 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLiUldKSzVyPUCuOVA4QTJiIN88US=> MlzKV2FPT0WU
MEG-01 NELCUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL4[JJ[UUN3ME2wMlUyOjF2IDFOwG0> NVfvUJdFW0GQR1XS
LB2241-RCC NX3ncIJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNUO3NVghKM7:TR?= NGGyUFFUSU6JRWK=
ACHN MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNUSwOlkhKM7:TR?= NX7wNol[W0GQR1XS
CTB-1 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7CXpRKSzVyPUCuOVQ5OiBizszN MV3TRW5ITVJ?
HT-1080 M1j6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\mTWM2OD1yLkW1N|Q6KCEQvF2= MUjTRW5ITVJ?
CHL-1 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNUW0OlUhKM7:TR?= MmrzV2FPT0WU
EW-3 NIqwOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PCVGlEPTB;MD61OVk{PSBizszN MYHTRW5ITVJ?
ES1 MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvOTWM2OD1yLk[3OFk5KCEQvF2= MVvTRW5ITVJ?
KASUMI-1 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjvdJNKSzVyPUCuO|I{OyBizszN NYG0N2FEW0GQR1XS
SW13 M{PVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[xTWM2OD1yLkezO|k5KCEQvF2= MYrTRW5ITVJ?
A3-KAW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LMd2lEPTB;MD63PVIxQCBizszN M4X5ZXNCVkeHUh?=
LB771-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojiTWM2OD1yLkizNVA1KCEQvF2= M4GwVXNCVkeHUh?=
OC-314 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXpTWM2OD1yLki2PVY2KCEQvF2= M2PSTXNCVkeHUh?=
MLMA NEDvcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzHTWM2OD1yLkmwOlc2KCEQvF2= MWTTRW5ITVJ?
KARPAS-45 M1zVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XoSWlEPTB;MD65NlQ3PiBizszN M4S0eXNCVkeHUh?=
CAL-27 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hZ3U2UUN3ME2wMlkzQTB4IDFOwG0> MUjTRW5ITVJ?
SK-NEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXd2lEPTB;MD65O|I1QCBizszN NF\pXnZUSU6JRWK=
COR-L105 NI[wVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPwTm5vUUN3ME2xMlAxOzl2IDFOwG0> NEnkUnZUSU6JRWK=
TI-73 NF7VR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL6TWM2OD1zLkCxOlUhKM7:TR?= NEnEPWNUSU6JRWK=
JVM-3 NHLKcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXmZYRXUUN3ME2xMlA2ODF5IDFOwG0> NXLVSlZ7W0GQR1XS
HAL-01 M3Gycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXhWmJDUUN3ME2xMlA5QDFiIN88US=> M1PTTHNCVkeHUh?=
QIMR-WIL M4TLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2Z2ZKSzVyPUGuNFkxPThiIN88US=> NVzHRWtkW0GQR1XS
HSC-3 M2DRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInHcmdKSzVyPUGuNVE4QDNiIN88US=> NYntTZZtW0GQR1XS
KY821 M1fJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LZNmlEPTB;MT6xN|M2OSBizszN MmLYV2FPT0WU
5637 M1mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i3cWlEPTB;MT6xN|gxOyBizszN MmjZV2FPT0WU
CAL-33 NX;wO4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjEeXlKSzVyPUGuNVk{ODJiIN88US=> M1rVVHNCVkeHUh?=
ES4 NUfEdohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1zLkKwO|khKM7:TR?= NXfDV29IW0GQR1XS
BHY Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:4UGlEPTB;MT6yNlg6OiBizszN MnzWV2FPT0WU
LB1047-RCC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jRXmlEPTB;MT6yN|c5PSBizszN MYTTRW5ITVJ?
H4 NUGyXZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMkSyOVUhKM7:TR?= NXLXSmRHW0GQR1XS
RPMI-8866 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DpUWlEPTB;MT6yOlExPiBizszN MkDnV2FPT0WU
HO-1-N-1 M2f4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMk[zOlkhKM7:TR?= NYjvZnBmW0GQR1XS
BB30-HNC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXBXHBKSzVyPUGuNlg4OTRiIN88US=> MWTTRW5ITVJ?
PC-14 NX[5[4R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Li[WlEPTB;MT6yPVIxPSBizszN M{jEfHNCVkeHUh?=
NUGC-3 NHHadoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HCTGlEPTB;MT6yPVM2PiBizszN MYrTRW5ITVJ?
A4-Fuk NVnsN2o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqxO3U4UUN3ME2xMlMxPzB2IDFOwG0> NYS3fpVNW0GQR1XS
MHH-NB-11 NH7xd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfhTWM2OD1zLkOxN|g{KCEQvF2= NF[0NoFUSU6JRWK=
KOSC-2 NITGb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwM{G3O|UhKM7:TR?= Mo\oV2FPT0WU
A498 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwNECxNVMhKM7:TR?= MXXTRW5ITVJ?
KG-1 NXHUboNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPvTWM2OD1zLkSxNlc{KCEQvF2= MVTTRW5ITVJ?
DEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTYeHZKSzVyPUGuOFM3PTdiIN88US=> NEDhTWxUSU6JRWK=
EW-16 NFzVWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfMfmhKSzVyPUGuOFM6PzNiIN88US=> MVrTRW5ITVJ?
BPH-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXRUIpRUUN3ME2xMlQ1QDB3IDFOwG0> NGDoRoVUSU6JRWK=
JAR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnp[2NKSzVyPUGuOFk{PiBizszN MWPTRW5ITVJ?
J-RT3-T3-5 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGc5lKSzVyPUGuOVE4OjJiIN88US=> NEPhcGZUSU6JRWK=
A375 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwNUG3O|IhKM7:TR?= M3nlW3NCVkeHUh?=
SW954 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIradHRKSzVyPUGuOVUxODdiIN88US=> M4fxcnNCVkeHUh?=
Ca9-22 M3;zSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwNU[yOkAh|ryP M3vLNXNCVkeHUh?=
D-566MG M1;RNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC2TWM2OD1zLkW3NVU2KCEQvF2= MWfTRW5ITVJ?
SCC-15 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOSGZKSzVyPUGuOlE5ODRiIN88US=> NEPjR5lUSU6JRWK=
HD-MY-Z NWrl[W9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD1zLk[zOVg1KCEQvF2= NGXUTIZUSU6JRWK=
HT-1376 NH3HRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHBdWpKSzVyPUGuOlQ{PiBizszN NX[4RXdLW0GQR1XS
CAL-54 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\CcGlEPTB;MT62OVcxQSBizszN MUTTRW5ITVJ?
ONS-76 NGLMcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XmSWlEPTB;MT62O|U2OSBizszN NY\uWZRIW0GQR1XS
EFO-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFwNki5NkAh|ryP NVT6enV5W0GQR1XS
769-P MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwNkm1PVYhKM7:TR?= MU\TRW5ITVJ?
MV-4-11 NWq0XVE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDQTWM2OD1zLk[5PFU3KCEQvF2= M2n0OHNCVkeHUh?=
NKM-1 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTTR2ZKSzVyPUGuO|E5ODJiIN88US=> NWnMdGlpW0GQR1XS
LOXIMVI NUL2WY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LoUWlEPTB;MT63OFU6QSBizszN NHjyeZNUSU6JRWK=
KYSE-140 NWHSUGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwN{W2OVUhKM7:TR?= MXHTRW5ITVJ?
ES5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFwOE[3OFchKM7:TR?= MlX0V2FPT0WU
BB65-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\2TWM2OD1zLki5PFQ6KCEQvF2= Mo[zV2FPT0WU
HN MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwOEm4O|QhKM7:TR?= NVG2Rod4W0GQR1XS
A101D Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSyNY1nUUN3ME2xMlk{PjJ6IDFOwG0> Mli4V2FPT0WU
LoVo MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwOUe2O|khKM7:TR?= NGSyVpZUSU6JRWK=
NCI-H526 MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fSUWlEPTB;MT65PVMzPSBizszN NFzhXJpUSU6JRWK=
NCI-H1693 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j2WWlEPTB;MT65PVg5QCBizszN NV34TlFkW0GQR1XS
OVCAR-4 NXPHdmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwMEC0N|UhKM7:TR?= NUi5cVRUW0GQR1XS
SK-HEP-1 NGjWbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTrbJVKSzVyPUKuNFA4PDViIN88US=> NEPscYVUSU6JRWK=
C2BBe1 NHHLRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrCN|NrUUN3ME2yMlA{Ozd{IDFOwG0> MWPTRW5ITVJ?
MEL-JUSO M2XD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{juZ2lEPTB;Mj6wOFQ3PCBizszN NEH3[YlUSU6JRWK=
MOLT-16 M2nnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwMEewOVghKM7:TR?= NUTVVJlsW0GQR1XS
NBsusSR NVTDNlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLGSnBKSzVyPUKuNFk5QDliIN88US=> NEfLU3hUSU6JRWK=
TK10 NUT3cFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\WfWY1UUN3ME2yMlE{PDV6IDFOwG0> NYXHblRZW0GQR1XS
CAL-39 M1PxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OyRmlEPTB;Mj6xOFQ5KCEQvF2= MnfHV2FPT0WU
NCI-H2030 M2rrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CyZ2lEPTB;Mj6xPFk4OyBizszN NEfxOVlUSU6JRWK=
HCT-116 M1XRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LyemlEPTB;Mj6yNlk5PCBizszN M3;xenNCVkeHUh?=
HTC-C3 NIXqSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5WoE2UUN3ME2yMlI3QDJ2IDFOwG0> M1r3b3NCVkeHUh?=
TYK-nu MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLzTWM2OD1{LkOwPVA6KCEQvF2= MmGwV2FPT0WU
FADU NGTHO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnriTWM2OD1{LkOyNlk3KCEQvF2= MUDTRW5ITVJ?
A431 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwM{ewNlUhKM7:TR?= NF;zeoxUSU6JRWK=
TE-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwM{iwNVkhKM7:TR?= M3rFOHNCVkeHUh?=
CAL-12T NFr4bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1juUGlEPTB;Mj60NFQyPyBizszN NIe4d4VUSU6JRWK=
DB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLnTWM2OD1{LkSyPFY6KCEQvF2= MVrTRW5ITVJ?
L-363 NIToUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jkNGlEPTB;Mj60N|UxPyBizszN NWDK[2syW0GQR1XS
MSTO-211H NFvQR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwNk[zPVEhKM7:TR?= MVTTRW5ITVJ?
SK-UT-1 M1vhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC4THpKSzVyPUKuO|E1ODZiIN88US=> NV[1[3dWW0GQR1XS
RPMI-8226 MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfaTWM2OD1{LkezNVY1KCEQvF2= M4rkUnNCVkeHUh?=
SF295 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMTWM2OD1{Lke0N|EhKM7:TR?= Mk\CV2FPT0WU
OS-RC-2 M17MR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHNTWM2OD1{Lke2Olc{KCEQvF2= NEWz[oxUSU6JRWK=
SK-MEL-24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7Dd5lsUUN3ME2yMlc5OjJ2IDFOwG0> NEPmXlNUSU6JRWK=
COR-L23 M1fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKy[VVzUUN3ME2yMlc6PDZ2IDFOwG0> NYXFSGpUW0GQR1XS
MHH-PREB-1 M{XofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3rWpdKSzVyPUKuPFAyPjFiIN88US=> NHnwe2ZUSU6JRWK=
SK-N-DZ M3;lfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XXUWlEPTB;Mj64NVY{QCBizszN NUe2WlJ4W0GQR1XS
OMC-1 NX;tO3dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwOEWwNFMhKM7:TR?= MWTTRW5ITVJ?
SK-MEL-2 NY\le5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDQcZNKSzVyPUKuPFkzPDNiIN88US=> MXHTRW5ITVJ?
SAS NH2xRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLYTWM2OD1{Lkm5OFE2KCEQvF2= MVfTRW5ITVJ?
EPLC-272H MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zDTmlEPTB;Mz6wNFI{PSBizszN MnvYV2FPT0WU
8505C NXO5TYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3H[Fg2UUN3ME2zMlExOzBzIDFOwG0> NYn6N5QyW0GQR1XS
EW-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrNb2xOUUN3ME2zMlE1Ojd5IDFOwG0> NWX6XnU5W0GQR1XS
YKG-1 NY\JRWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLrXXk2UUN3ME2zMlE1PzB4IDFOwG0> MkH6V2FPT0WU
EC-GI-10 NY\pXJNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzdWlEPTB;Mz6xO|I3OyBizszN MVXTRW5ITVJ?
SK-LU-1 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HDOGlEPTB;Mz6xPFQyQCBizszN NULIXIdLW0GQR1XS
P30-OHK NXzNeHk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:1fZpKSzVyPUOuNlAyOTdiIN88US=> MlzsV2FPT0WU
T-24 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnewTWM2OD1|LkKxPFE1KCEQvF2= NVTZUmRjW0GQR1XS
HSC-2 NELHfpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Txd2lEPTB;Mz6yNlI{OiBizszN NUK1RlNkW0GQR1XS
SK-MES-1 NEPSVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXdnBKSzVyPUOuNlQ5OjliIN88US=> MkDJV2FPT0WU
SW48 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPRfYRKSzVyPUOuNlU1QDZiIN88US=> NFHNZ4VUSU6JRWK=
ME-180 NIrpc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KzOmlEPTB;Mz6yOlA2OSBizszN MmjQV2FPT0WU
NCI-H2009 NG\OTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnDR5VsUUN3ME2zMlI6ODFiIN88US=> NYPmdIRoW0GQR1XS
HL-60 M2H6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzLTWM2OD1|LkK5NVMhKM7:TR?= MXHTRW5ITVJ?
NCI-N87 MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTCTWM2OD1|LkOwNVczKCEQvF2= MXzTRW5ITVJ?
GMS-10 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITH[2JKSzVyPUOuN|QxQDZiIN88US=> NXrnfWFlW0GQR1XS
SCH NED3OGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M360bmlEPTB;Mz60NFg1PCBizszN NFjYRWhUSU6JRWK=
C-33-A M375[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV61[YZWUUN3ME2zMlQyPDJzIDFOwG0> MmfKV2FPT0WU
NCI-H1703 NF[2Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwNEG4NVIhKM7:TR?= M2nYcHNCVkeHUh?=
A427 NEP4UJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSR3BTUUN3ME2zMlQ3OTJ2IDFOwG0> NGficIpUSU6JRWK=
MOLT-4 NWjlPHV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNwNEixPVkhKM7:TR?= MUjTRW5ITVJ?
NCI-H1792 NXHOXGVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL6c2ZKSzVyPUOuOFk5ODJiIN88US=> M3vufnNCVkeHUh?=
NCI-H1650 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwNUeyPUAh|ryP MUPTRW5ITVJ?
H-EMC-SS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLqTWM2OD1|LkW4OVY6KCEQvF2= NULOWlJJW0GQR1XS
SW982 MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNwNUi4NlkhKM7:TR?= M{PpT3NCVkeHUh?=
DSH1 NHjR[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;mcGlEPTB;Mz62OFEzOiBizszN NU[xZlJUW0GQR1XS
NOS-1 M2XTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRdlJlUUN3ME2zMlY1Ojd4IDFOwG0> MYnTRW5ITVJ?
BT-549 NV\6O2NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX6RXRCUUN3ME2zMlY4QDV2IDFOwG0> MYnTRW5ITVJ?
HuCCT1 M3Lpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DPRmlEPTB;Mz63OFE4PyBizszN Mo\1V2FPT0WU
NCI-H1755 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n3cmlEPTB;Mz65Olk4OSBizszN NHv1UmJUSU6JRWK=
KYSE-450 NFPsdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nEOGlEPTB;Mz65Olk6PyBizszN MUPTRW5ITVJ?
MIA-PaCa-2 NIfl[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvMNFBKSzVyPUOuPVczQSBizszN MX7TRW5ITVJ?
U-266 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknaTWM2OD1|Lkm3OFgyKCEQvF2= MnHxV2FPT0WU
Mewo NETQd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5SGZKSzVyPUSuNFY{PjFiIN88US=> M2fRSXNCVkeHUh?=
KYSE-520 NHHOOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRwMEm3PVkhKM7:TR?= NV;Dc2VOW0GQR1XS
MN-60 NHe4b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33mdWlEPTB;ND6xNFUxOSBizszN NUnsNG1NW0GQR1XS
Ramos-2G6-4C10 NGL1TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuzTWM2OD12LkG2O|M6KCEQvF2= M2fNUnNCVkeHUh?=
SK-MEL-1 NE[3cVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwMUi2PVUhKM7:TR?= NGjaXpRUSU6JRWK=
ABC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\EZ416UUN3ME20MlI{OzN|IDFOwG0> NEnPR3VUSU6JRWK=
CAKI-1 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTRwMkS1O|EhKM7:TR?= NXnmXWNQW0GQR1XS
HOS NULUUpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwMkmxOFEhKM7:TR?= NWrqSHVuW0GQR1XS
SN12C MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDOYREUUN3ME20MlM1OjR2IDFOwG0> MnHHV2FPT0WU
NB13 NIrVOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jxe2lEPTB;ND6zO|M2PSBizszN NI\rNGRUSU6JRWK=
M14 M2XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPTWHlKSzVyPUSuOFg4QTJiIN88US=> Mmq0V2FPT0WU
GP5d M4f6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGricJNKSzVyPUSuOVAyOiBizszN Mlf1V2FPT0WU
NCI-H720 NXvoSVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfwcJAxUUN3ME20MlU{PjF{IDFOwG0> NFTO[ItUSU6JRWK=
D-423MG M3\USmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfOfmhKSzVyPUSuOVM6OjRiIN88US=> M{D0[HNCVkeHUh?=
ChaGo-K-1 NUDTb5JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTRwNUm1OVkhKM7:TR?= NXjtZ2RyW0GQR1XS
MEL-HO NFK5Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRwNkGyOlEhKM7:TR?= M2XlOHNCVkeHUh?=
MHH-ES-1 NVO0RW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvCTWM2OD12Lk[yOFEyKCEQvF2= NW\4XHNEW0GQR1XS
KYSE-270 NGCySpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn61TWM2OD12Lk[1NVI3KCEQvF2= NVKyOlFOW0GQR1XS
GI-ME-N MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwN{GyPVEhKM7:TR?= NWnDTIhFW0GQR1XS
HOP-92 M1zReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1NYxKSzVyPUSuPFE{PzliIN88US=> NHXCXVVUSU6JRWK=
MKN1 NFHkd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f2dWlEPTB;ND64N|kyPCBizszN NHvienpUSU6JRWK=
ML-2 M4L4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwOEW2NlYhKM7:TR?= M3vPZXNCVkeHUh?=
RO82-W-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwOUK5PEAh|ryP Mn;xV2FPT0WU
G-361 NGnxeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTVwMEGwNFMhKM7:TR?= NEi0[2lUSU6JRWK=
HC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{POVmlEPTB;NT6wN|I6OSBizszN NETkb2pUSU6JRWK=
EW-24 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrCWZdKSzVyPUWuNFQxOzhiIN88US=> M{OyWnNCVkeHUh?=
HuP-T4 M1zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfadZVSUUN3ME21MlE1OzN2IDFOwG0> MYrTRW5ITVJ?
8-MG-BA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLDTWM2OD13LkO0NlghKM7:TR?= MoX0V2FPT0WU
HGC-27 NXnDSHlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7z[45MUUN3ME21MlM4Pjh{IDFOwG0> NEmycmZUSU6JRWK=
TE-12 NVHZbFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf4TWM2OD13LkSxOVg2KCEQvF2= M3TqTHNCVkeHUh?=
GT3TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHneZlHUUN3ME21MlQ1OjF{IDFOwG0> M3zROHNCVkeHUh?=
DOHH-2 NEPrSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;CUWlEPTB;NT60OVk5PiBizszN MojpV2FPT0WU
Ca-Ski NVj4OGhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQVppKSzVyPUWuOFYyOTViIN88US=> NUDxSlB6W0GQR1XS
A172 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTVwNUS5NlUhKM7:TR?= NVvXXWlkW0GQR1XS
EGI-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfxUGFKSzVyPUWuOVg6OzhiIN88US=> M3HLV3NCVkeHUh?=
MZ2-MEL NYXx[GExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fDcmlEPTB;NT62NVQ5PiBizszN NFe4eZFUSU6JRWK=
SW1710 M{\vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLjb4hKSzVyPUWuOlkxQTFiIN88US=> NY[3dWxmW0GQR1XS
HT-144 NV7ZXWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITTZ|VKSzVyPUWuO|I3QDViIN88US=> M1PJ[3NCVkeHUh?=
PA-1 NUnBc3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33YeGlEPTB;NT64NVg6OyBizszN MV;TRW5ITVJ?
HCC1937 NXHJRphRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHhRZpKSzVyPUWuPFM6OjliIN88US=> NF7UWmhUSU6JRWK=
SK-OV-3 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PKb2lEPTB;NT65NVEzOSBizszN NVT2foU4W0GQR1XS
K5 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTP[XZQUUN3ME22MlA2OTdiIN88US=> M4nyNHNCVkeHUh?=
NMC-G1 NIf3elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kcGlEPTB;Nj6wO|c6PyBizszN NF7JRnhUSU6JRWK=
MDA-MB-361 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfDTWM2OD14LkC5NlYyKCEQvF2= NITVS5hUSU6JRWK=
EKVX MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LGc2lEPTB;Nj6xN|UxOSBizszN MWrTRW5ITVJ?
ES7 NHryU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZwMU[xNVUhKM7:TR?= NIHNT|VUSU6JRWK=
KS-1 NYTkRY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnsTWM2OD14LkG3PVk{KCEQvF2= M{PmTXNCVkeHUh?=
NCI-H661 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrOcWRKSzVyPU[uNVgxQDFiIN88US=> MWfTRW5ITVJ?
ES8 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\NTWM2OD14LkG4NFgzKCEQvF2= NFz5OlZUSU6JRWK=
NCI-H23 NHrrenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\XNmlEPTB;Nj6yNVgyPiBizszN MUXTRW5ITVJ?
T47D MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZwMk[0OVchKM7:TR?= M4C3O3NCVkeHUh?=
A2780 NV3NS|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHG[4NpUUN3ME22MlM4PzBzIDFOwG0> M{XEfnNCVkeHUh?=
SCC-4 NWn6dZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG2W4lKSzVyPU[uOFM2PjFiIN88US=> MmTTV2FPT0WU
VA-ES-BJ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzaeot2UUN3ME22Mlk4ODR|IDFOwG0> M4\aOHNCVkeHUh?=
no-11 NHHiSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfpTWM2OD15LkG2OFEhKM7:TR?= M363cHNCVkeHUh?=
KU-19-19 NXn0SlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTdwMU[0O|YhKM7:TR?= NF3ZV5VUSU6JRWK=
MKN45 NYLFUnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfKTWM2OD15LkG4Olk6KCEQvF2= MUDTRW5ITVJ?
SCC-25 NUTO[pNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HpVGlEPTB;Nz6yN|QyPCBizszN MVvTRW5ITVJ?
ETK-1 NUDwUoI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXUTWM2OD15LkK1OVE1KCEQvF2= MnfIV2FPT0WU
COR-L88 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXKTWM2OD15LkK5N|E6KCEQvF2= NHPoSY9USU6JRWK=
8305C NEPmTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwM{K0PVIhKM7:TR?= MYfTRW5ITVJ?
Detroit562 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn2S|NSUUN3ME23MlMzPTB4IDFOwG0> MUPTRW5ITVJ?
SNU-449 M1PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqWZFKSzVyPUeuN|c3PTFiIN88US=> MY\TRW5ITVJ?
A704 NF7ud4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRNGlEPTB;Nz6zPFI4QCBizszN NHLrU4tUSU6JRWK=
D-502MG M4Pidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTdwM{i0O|MhKM7:TR?= MVrTRW5ITVJ?
NCI-H2228 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTdwNEG0OVghKM7:TR?= NX;MNVZXW0GQR1XS
CHP-212 NF;RdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj1UpVtUUN3ME23MlUyQDl4IDFOwG0> NEfxRo1USU6JRWK=
VMRC-RCZ NYHnNmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHrTWM2OD15LkW5NFY3KCEQvF2= NFjH[XNUSU6JRWK=
RPMI-2650 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDaTWM2OD15LkewN|EzKCEQvF2= NHy4XWNUSU6JRWK=
HCC2218 NHv0c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTdwN{KyOVghKM7:TR?= NEXDeopUSU6JRWK=
GCT MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3BfJpxUUN3ME23MlgzOTd{IDFOwG0> NHnJU4dUSU6JRWK=
SW780 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y5fWlEPTB;Nz65PVA3KCEQvF2= NH3mRZVUSU6JRWK=
KMOE-2 NFflemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0TWM2OD16LkC0NFchKM7:TR?= NHLGUG1USU6JRWK=
KYSE-180 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLzTWM2OD16LkC4OlQ5KCEQvF2= MoqyV2FPT0WU
TE-1 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRThwMUGwOVchKM7:TR?= MUfTRW5ITVJ?
OAW-42 NH\VTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\h[JhKSzVyPUiuNlU1QTZiIN88US=> NHj3cnRUSU6JRWK=
VM-CUB-1 NGrHe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr1fItKSzVyPUiuNlg{PjRiIN88US=> NYPER3NCW0GQR1XS
ECC10 NUftfVhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD16LkK4N|k4KCEQvF2= NWnaSml[W0GQR1XS
SW1573 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnWblczUUN3ME24MlQ1PDZ3IDFOwG0> MXPTRW5ITVJ?
NCI-H1299 M2PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRThwNUm3O|QhKM7:TR?= M4TsfnNCVkeHUh?=
ALL-PO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP4d2pUUUN3ME24MlY3PTl5IDFOwG0> NIrWVJFUSU6JRWK=
OVCAR-5 M1PNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRThwN{e2NlUhKM7:TR?= MV3TRW5ITVJ?
NCI-SNU-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLFUIpKSzVyPUiuPFMxODFiIN88US=> MVzTRW5ITVJ?
NCI-H2342 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDOS|JLUUN3ME24Mlg{OTBzIDFOwG0> MWPTRW5ITVJ?
RPMI-7951 M4eyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NET3emxKSzVyPUiuPFQyPTdiIN88US=> MYfTRW5ITVJ?
RCM-1 M3XEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwVWRiUUN3ME25MlA5OTR3IDFOwG0> MUnTRW5ITVJ?
Daoy NFHmVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInKZ2xKSzVyPUmuNVIxOjhiIN88US=> M4jGbHNCVkeHUh?=
HCC1395 NYjufFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T6S2lEPTB;OT6zNFg6PiBizszN MljQV2FPT0WU
786-0 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PjNWlEPTB;OT6zOlAzPiBizszN M3XpfXNCVkeHUh?=
GAMG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTlwNkW1N|QhKM7:TR?= MWHTRW5ITVJ?
HCC1954 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz3R2VKSzVyPUmuPFU5PTliIN88US=> NH3CWXhUSU6JRWK=
NCI-H1838 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;WTWM2OD17LkmwN|cyKCEQvF2= MUnTRW5ITVJ?
SW620 NHv2coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HRR2lEPTB;OT65OVM2PyBizszN MVzTRW5ITVJ?
NCI-H358 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi4Zmk6UUN3ME2xNE41OTl5IDFOwG0> NInxVolUSU6JRWK=
NCI-H1793 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\veoRKSzVyPUGwMlQzPDhiIN88US=> NU\HW21vW0GQR1XS
NCI-H1666 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G3T2lEPTB;MUCuOFM2PSBizszN M{jRbHNCVkeHUh?=
MZ7-mel NWHkPHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFyLkS3OVMhKM7:TR?= MoL1V2FPT0WU
MDA-MB-175-VII NIHsSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i2b2lEPTB;MUCuOlM6PiBizszN NVr6W5lSW0GQR1XS
COLO-829 NEjEdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFyLkiwNFQhKM7:TR?= M1:3bnNCVkeHUh?=
RVH-421 M1G2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDyUXdKSzVyPUGxMlE2OiBizszN M1\NWHNCVkeHUh?=
A549 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;HWIJ[UUN3ME2xNU4zPDd6IDFOwG0> M1HQeXNCVkeHUh?=
DJM-1 NHnmd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X1OGlEPTB;MUGuN|g{OyBizszN NWXxdI1TW0GQR1XS
IST-MEL1 NITKZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELQfnhKSzVyPUGxMlc{OTliIN88US=> NHTRPGRUSU6JRWK=
BEN NEHIbpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DLWmlEPTB;MUGuO|QxOiBizszN M3rE[nNCVkeHUh?=
KM12 M1LoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnQZZRXUUN3ME2xNU46ODlzIDFOwG0> MVrTRW5ITVJ?
HuO9 M{POW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2[mlEPTB;MUKuNFY3PiBizszN M1vCOXNCVkeHUh?=
U-2-OS MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PkR2lEPTB;MUKuNFg6OyBizszN NH;kUmZUSU6JRWK=
RH-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DBXGlEPTB;MUKuOFQ4OiBizszN Mk\LV2FPT0WU
NCI-H1048 M{LUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH5bnh7UUN3ME2xNk42PTB4IDFOwG0> MnX3V2FPT0WU
Mo-T NYrKSodOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7teYU1UUN3ME2xNk44OzB5IDFOwG0> NFniV4hUSU6JRWK=
KYSE-150 MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF{Lke0OVUhKM7:TR?= MWHTRW5ITVJ?
A388 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;Sd29oUUN3ME2xNk44PzF|IDFOwG0> Mle3V2FPT0WU
NCI-SNU-1 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnrTWM2OD1zMj64NFQ3KCEQvF2= NIDpOmZUSU6JRWK=
HEL MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\4RWlEPTB;MUKuPFIyOiBizszN MofQV2FPT0WU
UM-UC-3 M3z0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rHOGlEPTB;MUKuPFg4PCBizszN MoTCV2FPT0WU
TGBC24TKB M{nMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKySnNNUUN3ME2xN{4xOjZ5IDFOwG0> NU\yW28xW0GQR1XS
SW626 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHKdZFKSzVyPUGzMlI1QDViIN88US=> M17Uc3NCVkeHUh?=
ES6 NEPCTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv2RmY4UUN3ME2xN{4zPTF{IDFOwG0> NYnsNIVCW0GQR1XS
NCI-H2029 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vl[WlEPTB;MUOuPFExQCBizszN M3y0THNCVkeHUh?=
RXF393 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF|Lkm5NlchKM7:TR?= M4HwRXNCVkeHUh?=
HMV-II NEL2XpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF2LkC3PEAh|ryP MV3TRW5ITVJ?
EW-22 M{DhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF2LkG1NFIhKM7:TR?= NGHwPWVUSU6JRWK=
AsPC-1 M3vISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi4S25WUUN3ME2xOE42PjRiIN88US=> MYHTRW5ITVJ?
COLO-678 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkeyO|EhKM7:TR?= NUTYZ3YyW0GQR1XS
HCT-15 M3j4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvsTWM2OD1zND64PFU2KCEQvF2= M1XxVnNCVkeHUh?=
HCE-T NWfQTJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXHNmlIUUN3ME2xOE45QDd2IDFOwG0> MWfTRW5ITVJ?
SF539 NWq0coluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD1zNT6wOlQ{KCEQvF2= Mk\4V2FPT0WU
AU565 M1\4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0XmlEPTB;MUWuNlA6PiBizszN MYfTRW5ITVJ?
JVM-2 NVrsNHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fsSWlEPTB;MUWuNlY5OSBizszN NVPqW|NFW0GQR1XS
CaR-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13D[2lEPTB;MUWuOFQyOiBizszN MYjTRW5ITVJ?
23132-87 NGjYOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LPWGlEPTB;MUWuPFQ6PSBizszN NYrxcJVkW0GQR1XS
A673 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jO[2lEPTB;MUWuPVY{PiBizszN NFiyc|VUSU6JRWK=
KYSE-410 M2D5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGZoFqUUN3ME2xOk4xOjliIN88US=> NIfzPWtUSU6JRWK=
TE-9 NHH6XItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVyx[4REUUN3ME2xOk4xPjJiIN88US=> NWG1b3h4W0GQR1XS
LU-139 Mn;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjIZ3lKSzVyPUG2MlE5OjNiIN88US=> M4HGTXNCVkeHUh?=
GCIY NX:3SZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF4LkG5NVYhKM7:TR?= MnXhV2FPT0WU
JEG-3 M{jteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXLTWM2OD1zNj6yOUAh|ryP MXLTRW5ITVJ?
RT-112 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6yU5JKSzVyPUG2MlQyPDNiIN88US=> NWPTc4JFW0GQR1XS
COLO-680N M4e5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4LkWxNFghKM7:TR?= MWfTRW5ITVJ?
LU-134-A Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzZTWM2OD1zNj65PFk{KCEQvF2= NUGwSotDW0GQR1XS
MFM-223 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfMTWM2OD1zNz6xOVM2KCEQvF2= NF63SHRUSU6JRWK=
SF126 NXf5fIZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS1TWM2OD1zNz6xO|AyKCEQvF2= NUHjTXd7W0GQR1XS
NCI-H28 NXjSXnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LOTmlEPTB;MUeuNlA3PiBizszN NGPoS4lUSU6JRWK=
BFTC-905 NWmzT3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLEUXpOUUN3ME2xO{41QDN{IDFOwG0> MUHTRW5ITVJ?
SCC-9 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPoTWM2OD1zNz62Nlg2KCEQvF2= NXjTc|F1W0GQR1XS
KNS-62 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF5Lk[2NlkhKM7:TR?= NFj0SYFUSU6JRWK=
Hs-578-T NV\VS3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xc5NRUUN3ME2xO{45OTR7IDFOwG0> M1T2SnNCVkeHUh?=
D-336MG NHTIeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fxV2lEPTB;MUeuPFI6PCBizszN NVzXNJZOW0GQR1XS
NCI-H82 M2DJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16zT2lEPTB;MUiuNFE5OyBizszN NWXsZpBuW0GQR1XS
EFM-19 NIPUVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTaTWM2OD1zOD6wOVc4KCEQvF2= NVqxdllnW0GQR1XS
TGBC11TKB M1rONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[4OYhCUUN3ME2xPE4yODJzIDFOwG0> MYnTRW5ITVJ?
HEC-1 NGHwe4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT1SZZEUUN3ME2xPE4zQTF6IDFOwG0> MVzTRW5ITVJ?
HuP-T3 M1\wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6xTWM2OD1zOD61PVI6KCEQvF2= MVzTRW5ITVJ?
SF268 NGDxXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\iTWM2OD1zOD62O|AzKCEQvF2= NVy5RlZjW0GQR1XS
COLO-792 NIrzWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TobGlEPTB;MUiuO|k6PyBizszN NFv3[FFUSU6JRWK=
HLE MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH5TWM2OD1zOD64N|MyKCEQvF2= NWHGenNmW0GQR1XS
A204 NFjnbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojsTWM2OD1zOD65NVY1KCEQvF2= NWXOcZVWW0GQR1XS
CAL-72 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:4TWM2OD1zOT6wPFc4KCEQvF2= MUDTRW5ITVJ?
U031 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0eWRtUUN3ME2xPU41QTB7IDFOwG0> Mn3iV2FPT0WU
FTC-133 M1XWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXOTWM2OD1zOT65N|A1KCEQvF2= MkTkV2FPT0WU
SK-MEL-28 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Wz[GlEPTB;MkCuN|c3OSBizszN NETRNpdUSU6JRWK=
KGN NVfGVolXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnESGZqUUN3ME2yNE41Pjl7IDFOwG0> MmfaV2FPT0WU
HCC2998 NHKzS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD1{MT6zPVI3KCEQvF2= NIDx[3dUSU6JRWK=
GOTO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLsPWNKSzVyPUKxMlQ5PSBizszN MUjTRW5ITVJ?
AGS M3q3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJzLki0OVEhKM7:TR?= MVPTRW5ITVJ?
EW-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPBRnFEUUN3ME2yNk4yODJ{IDFOwG0> NH\vfIhUSU6JRWK=
P12-ICHIKAWA M1zUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jTOmlEPTB;MkKuNVYxOyBizszN MnjTV2FPT0WU
NCI-H1395 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInORllKSzVyPUKyMlI6ODdiIN88US=> NEDLdYJUSU6JRWK=
A2058 M2PSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG0bFlVUUN3ME2yNk41OzRiIN88US=> M3PnVHNCVkeHUh?=
SH-4 NV;J[VNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPRT3hKSzVyPUKyMlcxPDViIN88US=> M3HwTHNCVkeHUh?=
DoTc2-4510 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nsTGlEPTB;MkOuOlQ4OiBizszN NYrWfWtpW0GQR1XS
MMAC-SF MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP6WIhKSzVyPUKzMlY6OTFiIN88US=> M1jPWHNCVkeHUh?=
NCI-H510A NVrt[nVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7RO3h7UUN3ME2yN{44QTN7IDFOwG0> MUXTRW5ITVJ?
HDLM-2 M3q5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvw[G86UUN3ME2yOE4yPDZiIN88US=> MYTTRW5ITVJ?
KINGS-1 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruOW9lUUN3ME2yOE4zPDJiIN88US=> NWHtXnFtW0GQR1XS
NCI-H1648 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ2LkSwNlQhKM7:TR?= MVTTRW5ITVJ?
HCC1187 NYj0NIx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rMSmlEPTB;MkWuNFI{PSBizszN MnHKV2FPT0WU
BALL-1 NWLndodYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XtcmlEPTB;MkWuNlA3OiBizszN M376NHNCVkeHUh?=
SBC-1 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH1TWM2OD1{NT6yPVk{KCEQvF2= MlrOV2FPT0WU
BFTC-909 NWK3[|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISyVHJKSzVyPUK1MlM2PTFiIN88US=> NH;LZpJUSU6JRWK=
MOLT-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SwPWlEPTB;MkWuOlc1PCBizszN M375XnNCVkeHUh?=
SW1990 M3\IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfoPWJTUUN3ME2yOU46PjV3IDFOwG0> NELKRodUSU6JRWK=
DK-MG M2SzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ4LkC0OFMhKM7:TR?= NIixVFdUSU6JRWK=
TE-8 NIW5foZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1mzNWlEPTB;Mk[uNFY3QCBizszN NUH3U5VtW0GQR1XS
Becker MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2e|FKSzVyPUK2MlE2PzRiIN88US=> NYH6eZJCW0GQR1XS
KYSE-70 M2PpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjFTWM2OD1{Nj61N|E4KCEQvF2= NX;KWFA6W0GQR1XS
MKN7 M3zFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnxToJsUUN3ME2yO{44PDd7IDFOwG0> NY\w[pVMW0GQR1XS
D-392MG MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jQZ2lEPTB;MkeuO|Y6PCBizszN M3uyd3NCVkeHUh?=
NH-12 NUXhXJBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH5WFFKSzVyPUK4MlEzOjliIN88US=> Mo\3V2FPT0WU
EW-18 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInuVlhKSzVyPUK4MlIzOThiIN88US=> NHm1O3dUSU6JRWK=
LCLC-97TM1 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXEW4tKSzVyPUK4MlI4PjJiIN88US=> M1nXTXNCVkeHUh?=
NCI-H1770 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH1TWM2OD1{OD6zOVY3KCEQvF2= MYrTRW5ITVJ?
BT-20 NGG2cI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHvSY5KSzVyPUK4MlM3QDViIN88US=> NIm0dppUSU6JRWK=
DBTRG-05MG NGq3[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljLTWM2OD1{OD60PFM5KCEQvF2= M1nUdXNCVkeHUh?=
HPAF-II NIDmOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1{OD63O|khKM7:TR?= M2TZOnNCVkeHUh?=
SW837 NVLSeWZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\mTWM2OD1{OT6zN|g2KCEQvF2= MoG1V2FPT0WU
647-V MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G2NWlEPTB;MkmuO|AxOyBizszN NVHIcm9zW0GQR1XS
J82 MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qUVNTUUN3ME2yPU45ODF|IDFOwG0> NYCxS3dvW0GQR1XS
MC116 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6yfG1uUUN3ME2zNE4xPzN|IDFOwG0> NYXpT3d1W0GQR1XS
NCI-H69 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\hS2lEPTB;M{CuOlA6OyBizszN M33TfHNCVkeHUh?=
NB6 NUn1c3N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNzLkO2NlkhKM7:TR?= MYDTRW5ITVJ?
CAL-120 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN{LkSzNVchKM7:TR?= NYH1WGYyW0GQR1XS
U-87-MG NIfSN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPQd5FKSzVyPUOzMlAzPTFiIN88US=> MoS3V2FPT0WU
NCI-H1304 NH3ncY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK5TWM2OD1|Mz6wN|U1KCEQvF2= M{\VZnNCVkeHUh?=
YH-13 NIX0b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjsSXh2UUN3ME2zN{4zPTN3IDFOwG0> M3;OVXNCVkeHUh?=
RMG-I NGKyW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfUXJFUUUN3ME2zN{41Ojh3IDFOwG0> NXn2fGRqW0GQR1XS
LU-65 NHrVOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3RUYd3UUN3ME2zOE4yPDB6IDFOwG0> MnPDV2FPT0WU
GB-1 NVq0OJplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\5T2lEPTB;M{WuNFczQSBizszN MXjTRW5ITVJ?
DU-4475 M1i0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN3LkG1OVMhKM7:TR?= MmHnV2FPT0WU
SBC-5 M2j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN4LkW5NFIhKM7:TR?= NYfOd|Q3W0GQR1XS
OE33 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN5Lke1O|chKM7:TR?= M1rLeHNCVkeHUh?=
C8166 M1voZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPZTWM2OD1|OD61NlY4KCEQvF2= M1fvNXNCVkeHUh?=
COLO-684 NIK1UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTN6Lke0NlghKM7:TR?= M1HXdHNCVkeHUh?=
NCI-H1155 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN7LkC0O|EhKM7:TR?= MYjTRW5ITVJ?
ATN-1 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrzN2JKSzVyPUO5Mlc4QTJiIN88US=> MlfyV2FPT0WU
KARPAS-299 NIrUXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TmRWlEPTB;M{muPFM6KCEQvF2= NXHJ[XJmW0GQR1XS
KNS-81-FD M1\SOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRyLkO2NFQhKM7:TR?= M3;CZXNCVkeHUh?=
NCI-H1563 NHjKVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74eZhjUUN3ME20NU42ODN7IDFOwG0> MWHTRW5ITVJ?
NB14 M1rVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnRU4toUUN3ME20Nk44OjZ|IDFOwG0> NEX2S|ZUSU6JRWK=
COLO-800 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne5TWM2OD12Mj64OVE4KCEQvF2= NHzQc25USU6JRWK=
MS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiTWM2OD12Mz6wOFg{KCEQvF2= NXHoeI1pW0GQR1XS
OVCAR-8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfrTWM2OD12Mz62PFA6KCEQvF2= M4TXZnNCVkeHUh?=
SK-PN-DW MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpUGlEPTB;NEOuPFc4PiBizszN NHPvdJZUSU6JRWK=
G-402 NVToRVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfZcZFUUUN3ME20N{46ODB4IDFOwG0> Ml;SV2FPT0WU
NCI-H2291 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvEVldKSzVyPUS0MlgxOTdiIN88US=> NVvUTFZ2W0GQR1XS
PC-3 M13HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnPOlBtUUN3ME20OU45ODJ|IDFOwG0> NE\xVlJUSU6JRWK=
NCI-H1581 NVOxW|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR3Lkm4PFkhKM7:TR?= NGnmdGtUSU6JRWK=
SW1116 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTR5LkCxPFIhKM7:TR?= M4HFfXNCVkeHUh?=
ZR-75-30 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL1UG9ZUUN3ME20O{4xOjN7IDFOwG0> MonpV2FPT0WU
OCI-AML2 NHLOeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX3TWM2OD12Nz6wPVE5KCEQvF2= MlKxV2FPT0WU
MDA-MB-231 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtTWM2OD12Nz62NlQ6KCEQvF2= M2HlVHNCVkeHUh?=
ES3 NH\QTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR6LkO1NlkhKM7:TR?= MkP2V2FPT0WU
NCI-H630 NHPhcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTR7LkG3OFIhKM7:TR?= NXzmWJNZW0GQR1XS
OE19 NEf0XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG4eWtnUUN3ME20PU4zQTB{IDFOwG0> M13ETXNCVkeHUh?=
NCI-H1573 NIr3WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR7Lk[4OlEhKM7:TR?= M2TsNnNCVkeHUh?=
EW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTR7LkmwPFQhKM7:TR?= MmHoV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Src / Src / p-c-Abl / c-Abl / p-S6 / S6 / p-ERK / ERK / p-STAT3 / STAT3; 

PubMed: 27903968     


IMR-32, NB-19, SH-SY5Y, and SK-N-AS cells were treated with indicated concentrations of bosutinib for 0-8 hrs and the cells were lysed and subjected to immunoblotting with the indicated antibodies. β-Actin was used as a loading control in all experiments.

p-FAK / FAK / p-Pyk2 / p-p130Cas / p-AKT; 

PubMed: 18483306     


Western blot analysis of MDA-MB-468 whole cell extracts. Cells were treated with SKI-606 or 0.01% DMSO at the indicated concentrations for times up to 3 h prior to extraction. Immunoblots were probed as indicated with antibodies to phospho-Src (pY419), phospho-FAK (pYpY576/577 or pY925), phospho-Pyk2 (pY580), phospho-p130Cas (pY410), phospho-Stat3 (pY705), phospho-Akt (pS473), phospho-MAPK p44/42, beta-catenin, or PARP. Blots were re-probed with total anti-Src, anti-FAK, or anti-Stat3 antibodies, as indicated.

p-ABL / ABL ; 

PubMed: 28199182     


Cells were transfected with human wild-type ABL, and p190 and p210 variants of BCR-ABL, treated with inhibitors for 24 hr and analyzed for activating phosphorylation (p) by immunoblot. Actin and total levels of expressed kinases serve as loading controls. Cells transfected with empty plasmid serve as transfection control. 

27903968 18483306 28199182
Immunofluorescence
p-FAK / p-STAT3 / beta-catenin; 

PubMed: 18483306     


MDA-MB-231 cells were treated with 0.01% DMSO or 1 µM SKI-606 for 48 h then fixed, probed with antibodies to phospho-FAK (pY576/pY577), FAK, phospho-Stat3 (pY705) or beta-catenin as indicated, and stained with DAPI. Images were captured under fluorescence at 40x magnification.

18483306
Growth inhibition assay
Cell viability; 

PubMed: 24812339     


Proliferation curves for bosutinib, gefitinib and sorafenib in (A) H1650 and (B) H1975. 

IC50; 

PubMed: 27903968     


Six NB cell lines, IMR-32, NGP, NB-19, CHLA-255, SH-SY5Y, and SK-N-AS, were treated with increasing concentrations of bosutinib for 48 hrs. Cell viability was measured by performing the Cell Counting Kit-8 (CCK-8) assay.

24812339 27903968
In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]

Protocol

Kinase Assay:

[1]

- Collapse

The Src and Abl kinase assays:

The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.
Cell Research:

[2]

- Collapse
  • Cell lines: Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Nude female mice injected with K562 cells
  • Dosages: ~150 mg/kg/day
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (188.51 mM)
Water Insoluble
Ethanol ''''2 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage powder
in solvent
Synonyms N/A
Smiles COC1=C(Cl)C=C(Cl)C(=C1)NC2=C(C=NC3=CC(=C(OC)C=C23)OCCCN4CCN(C)CC4)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04258943 Not yet recruiting Drug: Bosutinib Philadelphia Chromosome Positive CML|Accelerated Phase Chronic Myelogenous Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia Children''s Oncology Group|Erasmus MC|Dutch Childhood Oncology Group- Early Clinical Trial Consortium|Innovative Therapies for Children with Cancer|Pfizer March 20 2020 Phase 1|Phase 2
NCT03023319 Recruiting Drug: Bosutinib|Drug: Pemetrexed Carcinoma Non-Small-Cell Lung|Mesothelioma|Bladder Cancer|Ovarian Cancer|Peritoneal Cancer|Thymoma|Thymus Cancer|Uterine Cervical Cancer Nagla Abdel Karim|Augusta University January 2020 Phase 1
NCT03888222 Active not recruiting Drug: Placebo Oral Tablet|Drug: Bosutinib Oral Tablet Dementia With Lewy Bodies Georgetown University|Alzheimer''s Association April 23 2019 Phase 2
NCT03854903 Recruiting Drug: Palbociclib|Drug: Bosutinib|Drug: Fulvestrant Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor Positive Breast Cancer Georgetown University|Pfizer April 1 2019 Phase 1
NCT03831776 Recruiting Drug: Bosutinib|Drug: Ropeginterferon Chronic Myeloid Leukemia St. Olavs Hospital|Haukeland University Hospital|Oslo University Hospital|University Hospital of North Norway|Helse Stavanger HF|Henri Mondor University Hospital|Hôpital René Huguenin|Hôpital Mignot Versailles Paris|Uppsala University Hospital|Odense University Hospital March 25 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can I give S1014 Bosutinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    For oral gavage, S1014 Bosutinib can be dissolved in 5% Tween 80+0.5% CMC Na at 30 mg/ml as a suspension.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) supplier | purchase Bosutinib (SKI-606) | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) manufacturer | order Bosutinib (SKI-606) | Bosutinib (SKI-606) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID